

Patient adherence and persistence with oral anticancer

Ca-A Cancer Journal for Clinicians

59, 56-66

DOI: [10.3322/caac.20004](https://doi.org/10.3322/caac.20004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia. <i>Drug Design, Development and Therapy</i> , 2009, 3, 241.	2.0	7
2	Cognitive Behavioral Therapy Alone and With Medication for Persistent Insomnia. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1053.	3.8	4
3	Adherence with adjuvant hormonal therapy for breast cancer. <i>Annals of Oncology</i> , 2009, 20, 401-402.	0.6	29
4	Strategies to Measure and Improve Patient Adherence in Clinical Trials. <i>Pharmaceutical Medicine</i> , 2009, 23, 289-297.	1.0	24
5	Chronotherapy and the molecular clock: Clinical implications in oncology. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 979-1001.	6.6	139
6	Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 1791-1800.	1.9	46
7	Development of the MASCC teaching tool for patients receiving oral agents for cancer. <i>Supportive Care in Cancer</i> , 2010, 18, 583-590.	1.0	43
8	Barriers to Adult Hemodialysis Patients' Self-Management of Oral Medications. <i>American Journal of Kidney Diseases</i> , 2010, 56, 547-557.	2.1	66
9	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib. <i>Journal of Clinical Oncology</i> , 2010, 28, 2381-2388.	0.8	802
10	Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. <i>Journal of Clinical Oncology</i> , 2010, 28, 2418-2422.	0.8	116
11	Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products. <i>Clinical Cancer Research</i> , 2010, 16, 4446-4451.	3.2	67
12	Nonadherence in Patients With Breast Cancer Receiving Oral Therapies. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 41-47.	0.3	28
14	Anticancer oral therapy: Emerging related issues. <i>Cancer Treatment Reviews</i> , 2010, 36, 595-605.	3.4	139
15	Adherence to biologic DMARD therapies in rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1367-1378.	1.4	60
16	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 825-835.	1.1	17
17	Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease. <i>Current Eye Research</i> , 2011, 36, 867-885.	0.7	62
18	Self-Reported Compliance with Capecitabine: Findings from a Prospective Cohort Analysis. <i>Oncology</i> , 2011, 80, 29-33.	0.9	54
19	Management of Treatment-Related Toxicity with Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 893-915.	0.9	21

#	ARTICLE	IF	CITATIONS
20	Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?. <i>Cancer Letters</i> , 2011, 300, 115-121.	3.2	35
21	The Challenges of Oral Agents as Antineoplastic Treatments. <i>Seminars in Oncology Nursing</i> , 2011, 27, 93-103.	0.7	79
22	Assessment and Measurement of Adherence to Oral Antineoplastic Agents. <i>Seminars in Oncology Nursing</i> , 2011, 27, 116-132.	0.7	33
23	Interventions to Promote Adherence With Oral Agents. <i>Seminars in Oncology Nursing</i> , 2011, 27, 133-141.	0.7	67
24	Challenges of ensuring adherence to oral therapy in patients with solid malignancies. <i>Community Oncology</i> , 2011, 8, 254-262.	0.2	4
25	Nursing Perspectives on Fulvestrant for the Treatment of Postmenopausal Women With Metastatic Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 674-681.	0.3	3
26	Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial. <i>Patient Preference and Adherence</i> , 2011, 5, 475.	0.8	12
27	Cancer patient-centered home care: a new model for health care in oncology. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 387.	0.9	46
28	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. <i>Blood</i> , 2011, 117, 3733-3736.	0.6	292
29	Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1872-1880.	0.5	132
30	Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 1558-1563.	2.9	61
31	Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 681-689.	1.1	86
32	Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. <i>Supportive Care in Cancer</i> , 2011, 19, 1009-1018.	1.0	108
33	Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?. <i>Oncology Reviews</i> , 2011, 5, 129-140.	0.8	13
34	Cost-related medication nonadherence and cost-saving strategies used by elderly Medicare cancer survivors. <i>Journal of Cancer Survivorship</i> , 2011, 5, 395-404.	1.5	51
35	The use of erlotinib in daily practice: a study on adherence and patients' experiences. <i>BMC Cancer</i> , 2011, 11, 284.	1.1	21
36	Non-adherence to drug therapy and drug acquisition costs in a national population - a patient-based register study. <i>BMC Health Services Research</i> , 2011, 11, 326.	0.9	47
37	The preferences and experiences of different bisphosphonate treatments in women with breast cancer. <i>Psycho-Oncology</i> , 2011, 20, 755-761.	1.0	9

#	ARTICLE	IF	CITATIONS
38	Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. <i>American Journal of Hematology</i> , 2011, 86, 38-47.	2.0	43
39	Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2011, 86, 471-474.	2.0	169
40	Preventing invasive breast cancer. <i>Cancer</i> , 2011, 117, 3064-3068.	2.0	6
41	Task allocation in cancer medication management – Integrating the pharmacist. <i>Patient Education and Counseling</i> , 2011, 83, 367-374.	1.0	15
42	Safe Handling of Oral Chemotherapeutic Agents in Clinical Practice: Recommendations From an International Pharmacy Panel. <i>Journal of Oncology Practice</i> , 2011, 7, 7-12.	2.5	85
43	Evaluation of medication compliance in patients on antidepressants at an outpatient tertiary cancer center setting. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 131-135.	0.5	3
44	Treatment adherence of cancer patients to orally administered chemotherapy: Insights from a Greek study using a self-reported questionnaire. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 304-311.	0.5	17
45	Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2534-2542.	0.8	297
46	Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions. <i>Journal of Oncology Practice</i> , 2011, 7, 46s-51s.	2.5	195
47	Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes. <i>Chemotherapy</i> , 2011, 57, 71-76.	0.8	11
48	Adherence to long-term adjuvant hormonal therapy for breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 709-715.	0.7	59
49	The use of capecitabine in daily practice: a study on adherence and patients' experiences. <i>Patient Preference and Adherence</i> , 2012, 6, 741.	0.8	10
50	Patient-Reported Discontinuation of Endocrine Therapy and Related Adverse Effects Among Women With Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e149-e157.	2.5	91
51	Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). <i>Annals of Oncology</i> , 2012, 23, 3075-3081.	0.6	26
52	Drugs during Pregnancy and Lactation: New Solutions to Serious Challenges. <i>Obstetrics and Gynecology International</i> , 2012, 2012, 1-2.	0.5	3
53	Adherence with Drug Therapy in Pregnancy. <i>Obstetrics and Gynecology International</i> , 2012, 2012, 1-5.	0.5	85
54	Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis. <i>Journal of Oncology Practice</i> , 2012, 8, 9s-15s.	2.5	16
55	The importance of nonpharmacogenetic factors in endocrine therapy. <i>Pharmacogenomics</i> , 2012, 13, 721-728.	0.6	10

#	ARTICLE	IF	CITATIONS
56	Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opinion on Drug Safety, 2012, 11, S49-S59.	1.0	38
57	Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. British Journal of Cancer, 2012, 107, 1249-1256.	2.9	62
58	Factors influencing medication adherence and hypertension management revisited: recent insights from cancer survivors. Hypertension Research, 2012, 35, 894-896.	1.5	8
59	Why are patients with chronic myeloid leukaemia (non-)adherent?. British Journal of Cancer, 2012, 107, 901-903.	2.9	8
60	Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Annals of Oncology, 2012, 23, 882-890.	0.6	107
61	Treatment adherence in chronic myeloid leukemia: a systematic review of the literature. Clinical Practice (London, England), 2012, 9, 87-100.	0.1	1
63	Feasibility Pilot on Medication Adherence and Knowledge in Ambulatory Patients With Gastrointestinal Cancer. Oncology Nursing Forum, 2012, 39, E373-E379.	0.5	28
64	Active home-based cancer treatment. Journal of Multidisciplinary Healthcare, 2012, 5, 137.	1.1	21
65	Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, S5-S20.	1.7	76
67	Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Research and Treatment, 2012, 136, 495-502.	1.1	52
68	What Happens Now? Psychosocial Care for Cancer Survivors After Medical Treatment Completion. Journal of Clinical Oncology, 2012, 30, 1215-1220.	0.8	196
69	Anticoagulants oraux aprÃ©s arthroplastie totale de hanche: la problÃ©matique de lâ€™observance. Revue De Chirurgie Orthopedique Et Traumatologique, 2012, 98, 171-178.	0.0	0
70	Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. British Journal of Cancer, 2012, 107, 904-909.	2.9	100
71	Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients with Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner. The Journal of Supportive Oncology, 2012, 10, 14-24.	2.3	46
72	Self-management Strategies Adopted by Breast Cancer Survivors to Improve their Adherence to Tamoxifen. Breast Journal, 2012, 18, 389-391.	0.4	4
73	High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. European Journal of Surgical Oncology, 2012, 38, 110-117.	0.5	47
74	Aprepitant for pruritus: drug-drug interactions matter. Lancet Oncology, The, 2012, 13, 964-965.	5.1	12
75	Adherence to BCR-ABL Inhibitors: Issues for CML Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 223-229.	0.2	31

#	ARTICLE	IF	CITATIONS
76	Oral thromboprophylaxis following total hip replacement: The issue of compliance. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2012, 98, 186-192.	0.9	16
77	Polymeric particulate technologies for oral drug delivery and targeting: A pathophysiological perspective. <i>Maturitas</i> , 2012, 73, 5-18.	1.0	34
78	Women's Experiences With Antiestrogen Therapy to Treat Breast Cancer. <i>Oncology Nursing Forum</i> , 2012, 39, 70-77.	0.5	20
79	Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). <i>Breast Cancer Research and Treatment</i> , 2012, 134, 419-428.	1.1	54
80	Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 459-478.	1.1	531
81	Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. <i>Medical Oncology</i> , 2012, 29, 1179-1185.	1.2	38
82	Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. <i>European Journal of Cancer Care</i> , 2012, 21, 10-19.	0.7	69
83	In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1198-1201.	1.0	37
84	Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 817-825.	0.4	51
85	A new taxonomy for describing and defining adherence to medications. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 691-705.	1.1	1,308
86	Oral Cancer Chemotherapy Adherence and Adherence Assessment Tools: a Report from North Central Cancer Group Trial N0747 and a Systematic Review of the Literature. <i>Journal of Cancer Education</i> , 2013, 28, 770-776.	0.6	20
87	What Should We Do to Improve Patients' Adherence?. <i>Journal of Experimental and Clinical Medicine</i> , 2013, 5, 127-130.	0.2	15
88	Pectin-coated chitosan microgels crosslinked on superhydrophobic surfaces for 5-fluorouracil encapsulation. <i>Carbohydrate Polymers</i> , 2013, 98, 331-340.	5.1	51
89	Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. <i>Cancer Treatment Reviews</i> , 2013, 39, 610-621.	3.4	157
90	Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia. <i>Supportive Care in Cancer</i> , 2013, 21, 2351-2357.	1.0	25
92	Has the time come for metronomics in low-income and middle-income countries?. <i>Lancet Oncology</i> , 2013, 14, e239-e248.	5.1	142
93	Survey of oral chemotherapy safety and adherence practices of hospitals in Spain. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 1236-1244.	1.0	12
94	Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 455-459.	1.1	19

#	ARTICLE	IF	CITATIONS
95	Oral delivery of anticancer drugs I: general considerations. <i>Drug Discovery Today</i> , 2013, 18, 25-34.	3.2	58
96	Exploring ART Intake Scenes in a Human Rights-Based Intervention to Improve Adherence: A Randomized Controlled Trial. <i>AIDS and Behavior</i> , 2013, 17, 181-192.	1.4	19
97	Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study. <i>Lung Cancer</i> , 2013, 81, 280-287.	0.9	44
98	Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 390-398.	1.1	48
99	Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement. <i>Clinical Pharmacokinetics</i> , 2013, 52, 399-414.	1.6	118
100	Treating Chronic Myeloid Leukemia. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, E13-E20.	0.3	15
101	Smartphone medication adherence apps: Potential benefits to patients and providers. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2013, 53, 172-181.	0.7	365
102	Oral delivery of anticancer drugs: Challenges and opportunities. <i>Journal of Controlled Release</i> , 2013, 170, 15-40.	4.8	403
103	Adherence Rates and Correlates in Long-term Hormonal Therapy. <i>Vitamins and Hormones</i> , 2013, 93, 353-375.	0.7	4
104	An evaluation of the anti-tumor efficacy of oleanolic acid-loaded PEGylated liposomes. <i>Nanotechnology</i> , 2013, 24, 235102.	1.3	26
105	Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors. <i>Oncology</i> , 2013, 84, 67-74.	0.9	18
107	Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study. <i>BMJ Open</i> , 2013, 3, e003139.	0.8	37
109	Predictors of Adherence to Behavioral Counseling and Medication Among Female Prisoners Enrolled in a Smoking Cessation Trial. <i>Journal of Correctional Health Care</i> , 2013, 19, 236-247.	0.2	18
110	Breast cancer survivorship symptom management: current perspective and future development. <i>Breast Cancer Management</i> , 2013, 2, 71-81.	0.2	16
111	Identifying Strategies to Optimize Care With Oral Cancer Therapy. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, 629-636.	0.3	11
112	Time to Get Serious About Improving the Safety of Oral Chemotherapy. <i>Journal of Oncology Practice</i> , 2013, 9, 1s-2s.	2.5	3
113	The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. <i>Annals of Oncology</i> , 2013, 24, 1505-1512.	0.6	106
114	2013 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards Including Standards for the Safe Administration and Management of Oral Chemotherapy. <i>Journal of Oncology Practice</i> , 2013, 9, 5s-13s.	2.5	135

#	ARTICLE	IF	CITATIONS
115	Pretreatment Predictors of Short-Term Nonadherence to Oral Hormonal Therapy for Women With Breast Cancer. <i>Nursing Research</i> , 2013, 62, 243-251.	0.8	11
116	Adherence to Adjuvant Hormonal Therapy and Its Relationship to Breast Cancer Recurrence and Survival Among Low-income Women. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 181-187.	0.6	61
117	Improving adherence to oral anticancer therapy. <i>Nursing</i> , 2013, 43, 31-36.	0.2	2
118	Medication Errors in the Home: A Multisite Study of Children With Cancer. <i>Pediatrics</i> , 2013, 131, e1405-e1414.	1.0	76
119	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27â€”A Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1398-1404.	0.8	218
120	2013 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards Including Standards for the Safe Administration and Management of Oral Chemotherapy. <i>Oncology Nursing Forum</i> , 2013, 40, 225-233.	0.5	57
121	Multisite Parent-Centered Risk Assessment to Reduce Pediatric Oral Chemotherapy Errors. <i>Journal of Oncology Practice</i> , 2013, 9, e1-e7.	2.5	24
122	Preliminary Validation of Selfâ€”assessment Tool to Measure Imatinib Adherence in Patients with Chronic Myeloid Leukemia. <i>Pharmacotherapy</i> , 2013, 33, 152-156.	1.2	19
123	Adherence Issues for Oral Antineoplastics. <i>American Journal of Lifestyle Medicine</i> , 2013, 7, 206-222.	0.8	1
124	The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. <i>British Journal of Cancer</i> , 2013, 109, 1172-1180.	2.9	99
125	Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. <i>British Journal of Cancer</i> , 2013, 108, 1515-1524.	2.9	242
126	Patient-Oncologist Alliance, Psychosocial Well-Being, and Treatment Adherence Among Young Adults With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1683-1689.	0.8	82
127	Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment. <i>World Journal of Surgical Oncology</i> , 2013, 11, 287.	0.8	11
128	Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. <i>Patient Preference and Adherence</i> , 2013, 7, 675.	0.8	273
129	Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. <i>Patient Preference and Adherence</i> , 2013, 7, 391.	0.8	17
130	Determinants of patient adherence: a review of systematic reviews. <i>Frontiers in Pharmacology</i> , 2013, 4, 91.	1.6	482
131	Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 477-484.	2.2	21
132	Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy. <i>Patient Preference and Adherence</i> , 2014, 8, 917.	0.8	20

#	ARTICLE	IF	CITATIONS
133	Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a U.S. Administrative Claims Database. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 603-610.	2.2	23
134	Fatores associados à persistência à terapia hormonal em mulheres com câncer de mama. <i>Revista De Saude Publica</i> , 2014, 48, 284-295.	0.7	63
135	STUDY ON ADHERENCE TO CAPECITABINE AMONG PATIENTS WITH COLORECTAL CANCER AND METASTATIC BREAST CANCER. <i>Arquivos De Gastroenterologia</i> , 2014, 51, 186-191.	0.3	23
136	Oral anticancer agent medication adherence by outpatients. <i>Oncology Letters</i> , 2014, 8, 2318-2324.	0.8	13
137	Adherence and patients' experiences with the use of oral anticancer agents. <i>Acta Oncológica</i> , 2014, 53, 259-267.	0.8	68
138	Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. <i>Canadian Journal of Surgery</i> , 2014, 57, 26-32.	0.5	65
139	Widening educational differences in cancer survival in Norway. <i>European Journal of Public Health</i> , 2014, 24, 270-275.	0.1	10
140	Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. <i>Current Medical Research and Opinion</i> , 2014, 30, 1345-1352.	0.9	41
141	Nurses' practice patterns in relation to adherence-enhancing interventions in stem cell transplant care: a survey from the Nurses Group of the European Group for Blood and Marrow Transplantation. <i>European Journal of Cancer Care</i> , 2014, 23, 607-615.	0.7	9
142	Improving Adherence to Oral Cancer Therapy in Clinical Practice. <i>Pharmacotherapy</i> , 2014, 34, 481-494.	1.2	67
143	Sexual Problems During the First 2 Years of Adjuvant Treatment with Aromatase Inhibitors. <i>Journal of Sexual Medicine</i> , 2014, 11, 3102-3111.	0.3	93
144	Ethnic disparities in adherence to breast cancer survivorship surveillance care. <i>Cancer</i> , 2014, 120, 894-900.	2.0	30
145	The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	85
146	Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. <i>Annals of Oncology</i> , 2014, 25, 564-577.	0.6	160
147	Retrospective Study of the Prevalence, Predictors, and Consequences of Nonadherence With Lapatinib in Women With Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab. <i>Journal of Pharmacy Technology</i> , 2014, 30, 21-30.	0.5	0
148	Influence of Patient and Treatment Factors on Adherence to Adjuvant Endocrine Therapy in Breast Cancer. <i>Oncology Nursing Forum</i> , 2014, 41, 274-285.	0.5	105
149	Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2014, 38, 294-298.	0.4	32
150	Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy. <i>Journal of Controlled Release</i> , 2014, 176, 94-103.	4.8	63

#	ARTICLE	IF	CITATIONS
151	Mejorar la adherencia al tratamiento antineoplásico oral. Nursing (Ed Española), 2014, 31, 53-57.	0.0	0
152	Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings. Cancer Prevention Research, 2014, 7, 378-387.	0.7	147
153	Patient Adherence With Oral Oncolytic Therapies. Seminars in Oncology Nursing, 2014, 30, 190-199.	0.7	5
154	Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine. Journal of Oncology Pharmacy Practice, 2014, 20, 249-256.	0.5	25
155	Interventions for preparing patients for chemotherapy and radiotherapy: a systematic review. Supportive Care in Cancer, 2014, 22, 2297-2308.	1.0	54
156	Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Research and Treatment, 2014, 145, 525-534.	1.1	91
157	Adherence to hormone therapy among women with breast cancer. BMC Cancer, 2014, 14, 397.	1.1	53
158	Current nursing practice for patients on oral chemotherapy: a multicenter survey in Japan. BMC Research Notes, 2014, 7, 259.	0.6	12
159	Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials, 2014, 35, 6543-6552.	5.7	43
160	Adherence enhancing interventions for oral anticancer agents: A systematic review. Cancer Treatment Reviews, 2014, 40, 102-108.	3.4	65
161	Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 54-59.	0.7	17
162	Adherence influencing factors in patients taking oral anticancer agents: A systematic review. Cancer Epidemiology, 2014, 38, 214-226.	0.8	62
163	Mechanisms of P-Glycoprotein Alteration During Anticancer Treatment: Role in the Pharmacokinetic and Pharmacological Effects of Various Substrate Drugs. Journal of Pharmacological Sciences, 2014, 125, 242-254.	1.1	23
165	Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting. Oncology Letters, 2015, 9, 2341-2346.	0.8	5
166	A Structured Nursing Intervention to Address Oral Chemotherapy Adherence in Patients With Non-Small Cell Lung Cancer. Oncology Nursing Forum, 2015, 42, 383-389.	0.5	29
167	Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review. American Journal of Public Health, 2015, 105, e4-e15.	1.5	102
168	Oral antineoplastic agents: how do we care about adherence?. British Journal of Clinical Pharmacology, 2015, 80, 1289-1302.	1.1	53
169	Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance. Journal of Global Oncology, 2015, 1, 65-72.	0.5	3

#	ARTICLE	IF	CITATIONS
170	Gastrointestinal toxicities from targeted therapies. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 163-167.	0.5	7
171	FACTORS INFLUENCING ADHERENCE TO IMATINIB IN INDIAN CHRONIC MYELOID LEUKEMIA PATIENTS: A CROSS-SECTIONAL STUDY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015013.	0.5	26
172	Strategies to improve adherence to treatment in adolescents and young adults with cancer: a systematic review. <i>Clinical Oncology in Adolescents and Young Adults</i> , 0, , 35.	0.8	21
173	Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. <i>Patient Preference and Adherence</i> , 2015, 9, 561.	0.8	23
174	Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 515-522.	0.5	17
175	Interventions for adherence with oral chemotherapy in hematological malignancies: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2015, 11, 303-314.	1.5	23
176	Electronic Monitoring of Medication Adherence in Early Maintenance Phase Treatment for Pediatric Leukemia and Lymphoma: Identifying Patterns of Nonadherence. <i>Journal of Pediatric Psychology</i> , 2015, 40, 75-84.	1.1	30
177	New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv245.	3.0	21
178	Adherence and Patients' Attitudes to Oral Anticancer Drugs: A Prospective Series of 201 Patients Focusing on Targeted Therapies. <i>Oncology</i> , 2015, 88, 1-8.	0.9	29
179	The role of observational studies in optimizing the clinical management of chronic myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 3-14.	1.1	22
180	Adherence to adjuvant endocrine therapy: Is it a factor for ethnic differences in breast cancer outcomes in New Zealand?. <i>Breast</i> , 2015, 24, 62-67.	0.9	22
181	Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an ItalianÁSurvey. <i>Clinical Breast Cancer</i> , 2015, 15, e131-e137.	1.1	27
182	Optimizing cancer care through mobile health. <i>Supportive Care in Cancer</i> , 2015, 23, 2183-2188.	1.0	70
183	Inpatient and Outpatient Pharmacy Monitoring of Oral Antineoplastic Medications. <i>Hospital Pharmacy</i> , 2015, 50, 91-92.	0.4	3
184	Putting Evidence Into Practice: Evidence-Based Interventions for Oral Agents for Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 60-72.	0.3	19
185	Extending the Quality and Safety Agenda From Parenteral to Oral Chemotherapy. <i>Journal of Oncology Practice</i> , 2015, 11, 198-201.	2.5	8
186	Household Net Worth, Racial Disparities, and Hormonal Therapy Adherence Among Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1053-1059.	0.8	102
187	Engineering precision. <i>Science Translational Medicine</i> , 2015, 7, 289ed6.	5.8	10

#	ARTICLE	IF	CITATIONS
188	Overview of the Challenges Related to Oral Agents for Cancer and Their Impact on Adherence. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 37-40.	0.3	22
189	Assessment and Measurement of Medication Adherence: Oral Agents for Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 47-52.	0.3	26
190	Adherence, exposure and patients'™ experiences with the use of erlotinib in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1481-1491.	1.2	35
191	Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 453-464.	1.1	9
192	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. <i>Journal of Clinical Oncology</i> , 2015, 33, 2254-2261.	0.8	232
193	Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study. <i>Palliative and Supportive Care</i> , 2015, 13, 255-263.	0.6	31
194	Patterns of use of oral anticancer treatments in France: a Retrospective Analysis of Cancer Treatments given ORally from 2004 to 2012 (Re-ACTOR study). <i>Current Medical Research and Opinion</i> , 2015, 31, 323-332.	0.9	8
195	Adherence to oral anticancer chemotherapy: What influences patients'™ over or non-adherence? Analysis of the OCTO study through quantitative™ qualitative methods. <i>BMC Research Notes</i> , 2015, 8, 291.	0.6	20
196	Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors. <i>European Journal of Cancer</i> , 2015, 51, 1890-1896.	1.3	19
197	A critical ethnography of communication processes involving the management of oral chemotherapeutic agents by patients with a primary diagnosis of colorectal cancer: study protocol. <i>Journal of Advanced Nursing</i> , 2015, 71, 922-932.	1.5	3
198	Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies. <i>Experimental Hematology and Oncology</i> , 2015, 4, 15.	2.0	4
199	Developing nanocrystals for cancer treatment. <i>Nanomedicine</i> , 2015, 10, 2537-2552.	1.7	104
200	Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG). <i>European Journal of Cancer</i> , 2015, 51, 2491-2500.	1.3	35
201	Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 227-235.	0.5	22
202	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 23-32.	1.8	20
203	Risk of Nondherence to Diabetes Medications Among Medicare Advantage Enrollees: Development of a Validated Risk Prediction Tool. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1293-1301.	0.5	3
204	Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 979-990.	0.5	15
205	Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 243-251.	1.1	40

#	ARTICLE	IF	CITATIONS
206	Factors Influencing Adherence in Cancer Patients Taking Oral Tyrosine Kinase Inhibitors. <i>Cancer Nursing</i> , 2016, 39, 153-162.	0.7	33
207	Improving Adherence to Adjuvant Endocrine Therapy in Breast Cancer Through a Therapeutic Educational Approach: A Feasibility Study. <i>Oncology Nursing Forum</i> , 2016, 43, E94-E103.	0.5	12
208	The Association Between Patient-Reported and Objective Oral Anticancer Medication Adherence Measures: A Systematic Review. <i>Oncology Nursing Forum</i> , 2016, 43, 576-582.	0.5	29
209	Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review. <i>Clinical Breast Cancer</i> , 2016, 16, 247-255.e3.	1.1	55
210	Pharmacists' perceived knowledge of and confidence in dispensing oral antineoplastic agents. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2016, 56, 141-144.e2.	0.7	10
211	Medication Adherence. , 2016, , 1-21.		4
212	Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 366-371.e3.	0.2	37
213	What does it take to provide cancer patients with comprehensive medication therapy management services for oral chemotherapy?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 413-415.	1.0	3
214	Oral Chemotherapy in Patients with Hematological Malignancies: Care Process, Pharmacoeconomic and Policy Implications. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 288-294.	1.2	11
215	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016, 6, S1-S10.	0.4	10
216	The 21st century revolution in CLL: Why this matters to patients. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 122-132.	0.7	3
217	Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data. <i>Cancer Medicine</i> , 2016, 5, 1776-1782.	1.3	6
218	Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 59-63.	0.7	9
219	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 43-73.	157.7	497
221	Medication Therapy Management for Patients Receiving Oral Chemotherapy Agents at a Community Oncology Center: A Pilot Study. <i>Hospital Pharmacy</i> , 2016, 51, 721-733.	0.4	16
222	The Experience of Initiating Oral Adjuvant Treatment for Estrogen Receptor-Positive Breast Cancer. <i>Oncology Nursing Forum</i> , 2016, 43, E143-E152.	0.5	2
223	Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice. <i>SpringerPlus</i> , 2016, 5, 270.	1.2	5
224	Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 319-325.	12.5	179

#	ARTICLE	IF	CITATIONS
225	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 611-635.	0.8	651
226	A Systematic Review of Adherence to Oral Antineoplastic Therapies. <i>Oncologist</i> , 2016, 21, 354-376.	1.9	254
227	Adherence to oral anticancer agents: Healthcare providers' perceptions, beliefs and shared decision making in Belgium and the Netherlands. <i>Acta Oncologica</i> , 2016, 55, 437-443.	0.8	8
228	Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2016, 45, 1-6.	3.4	21
229	To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 247-262.	2.0	48
230	Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 511-516.	0.5	32
231	Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 43-55.	0.5	6
232	Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study. <i>European Journal of Cancer Care</i> , 2017, 26, e12413.	0.7	28
233	Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. <i>European Journal of Cancer Care</i> , 2017, 26, e12339.	0.7	25
234	Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents. <i>European Journal of Cancer Care</i> , 2017, 26, e12463.	0.7	19
235	New oral targeted therapies for metastatic breast cancer disrupt the traditional patients' management-A healthcare providers' view. <i>European Journal of Cancer Care</i> , 2017, 26, e12624.	0.7	4
236	Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. <i>Future Oncology</i> , 2017, 13, 415-423.	1.1	18
237	Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial. <i>BMC Health Services Research</i> , 2017, 17, 133.	0.9	16
238	The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices. <i>Supportive Care in Cancer</i> , 2017, 25, 1797-1807.	1.0	34
239	Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. <i>Cancer</i> , 2017, 123, 1453-1463.	2.0	65
240	Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 629-635.	0.8	15
241	Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102). <i>Clinical Colorectal Cancer</i> , 2017, 16, 85-92.	1.0	14
242	Oral Agents for Cancer Treatment. <i>Nursing Clinics of North America</i> , 2017, 52, 115-131.	0.7	9

#	ARTICLE	IF	CITATIONS
243	In our March 2017 issue of EJCC â€¦. European Journal of Cancer Care, 2017, 26, e12678.	0.7	0
244	Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Medical Oncology, 2017, 34, 104.	1.2	35
245	Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer. Current Breast Cancer Reports, 2017, 9, 100-110.	0.5	14
246	Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Research and Treatment, 2017, 165, 247-260.	1.1	102
247	Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs, 2017, 77, 1091-1103.	4.9	116
248	Costâ€related medication nonadherence among adolescent and young adult cancer survivors. Cancer, 2017, 123, 2726-2734.	2.0	65
249	Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. Pharmacogenomics, 2017, 18, 821-830.	0.6	12
250	Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles. Therapeutic Delivery, 2017, 8, 29-47.	1.2	15
251	NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction. Cancer Prevention Research, 2017, 10, 625-634.	0.7	22
252	Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors. Oncology Nursing Forum, 2017, 44, E232-E240.	0.5	3
253	Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil. Clinical Journal of Oncology Nursing, 2017, 21, E30-E37.	0.3	2
254	Enhancing Nursesâ€™ Oral Therapy Practice in 4 Latin American Countries. Cancer Nursing, 2017, 40, E49-E59.	0.7	0
255	National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1233-1241.	0.9	16
256	Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. BMC Cancer, 2017, 17, 122.	1.1	30
257	Adherence with capecitabine: A population-based analysis based on prescription refill data. Journal of Oncology Pharmacy Practice, 2017, 23, 284-287.	0.5	2
258	The patientâ€™ provider discordance in patientsâ€™ needs assessment: a qualitative study in breast cancer patients receiving oral chemotherapy. Journal of Clinical Nursing, 2017, 26, 125-132.	1.4	17
259	Leveraging Physiology for Precision Drug Delivery. Physiological Reviews, 2017, 97, 189-225.	13.1	125
260	Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer. Oncology Research, 2017, 25, 1625-1631.	0.6	12

#	ARTICLE	IF	CITATIONS
261	Nanotechnology for oral delivery of anticancer drugs: an insight potential. , 2017, , 467-510.		6
262	Subjective patient-reported versus objective adherence to subcutaneous interferon β -1a in multiple sclerosis using RebiSmart [®] : the CORE study. BMC Neurology, 2017, 17, 171.	0.8	8
263	Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Preference and Adherence, 2017, Volume 11, 305-322.	0.8	106
264	Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer. Journal of Oncology Practice, 2017, 13, e474-e485.	2.5	101
265	Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Research and Treatment, 2018, 169, 537-548.	1.1	58
266	Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas. Breast Cancer Research and Treatment, 2018, 169, 573-586.	1.1	14
267	Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. Gynecologic Oncology, 2018, 150, 173-179.	0.6	19
268	The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group. Biology of Blood and Marrow Transplantation, 2018, 24, 914-922.	2.0	24
269	Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib. Clinical Colorectal Cancer, 2018, 17, e531-e539.	1.0	20
270	Chemotherapy medication errors. Lancet Oncology, The, 2018, 19, e191-e199.	5.1	137
271	Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit. European Journal of Cancer Care, 2018, 27, e12447.	0.7	5
272	Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. Journal of Oncology Pharmacy Practice, 2018, 24, 98-109.	0.5	39
273	Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents. Journal of Oncology Pharmacy Practice, 2018, 24, 371-378.	0.5	19
274	Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clinical Pharmacokinetics, 2018, 57, 1-6.	1.6	29
275	Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. Cancer, 2018, 124, 364-373.	2.0	31
276	Adherence to Oral Medications During Maintenance Therapy Among Children and Adolescents With Acute Lymphoblastic Leukemia: A Medication Refill Analysis. Journal of Pediatric Oncology Nursing, 2018, 35, 86-93.	1.5	19
277	Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 508-512.	0.6	11
278	Variation in Adherence Measures to Imatinib Therapy. Journal of Global Oncology, 2018, 4, 1-10.	0.5	2

#	ARTICLE	IF	CITATIONS
279	Effects of a Medication Management Program for Cancer Patients Receiving Oral Chemotherapy. <i>Asian Oncology Nursing</i> , 2018, 18, 94.	0.2	1
280	Exploring behaviors, treatment beliefs, and barriers to oral chemotherapy adherence among adult leukemia patients in a rural outpatient setting. <i>BMC Research Notes</i> , 2018, 11, 843.	0.6	5
281	Oncologist perspectives on chemotherapyâ€­induced nausea and vomiting (CINV) management and outcomes: A quantitative market researchâ€­based survey. <i>Cancer Reports</i> , 2018, 1, e1127.	0.6	31
282	Implementation and evaluation of a pharmacistâ€­led oral anticancer medication management clinic. <i>Journal of Pharmacy Practice and Research</i> , 2018, 48, 509-515.	0.5	2
283	Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1875-1887.	0.8	4
284	Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer. <i>Psycho-Oncology</i> , 2018, 27, 2096-2103.	1.0	15
285	Number of Unused Medications at the Time of Last Admission: A Prospective Observational Study in a Single Palliative Care Unit. <i>American Journal of Hospice and Palliative Medicine</i> , 2018, 35, 1498-1504.	0.8	2
286	Evaluation of mobile phone applications to support medication adherence and symptom management in oncology patients. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27278.	0.8	52
287	Adolescents and young adults with cancer: aspects of adherence – a questionnaire study. <i>Adolescent Health, Medicine and Therapeutics</i> , 2018, Volume 9, 77-85.	0.7	15
288	Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 23.	0.6	38
289	Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 319-327.	1.1	16
290	Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1267-1277.	0.9	3
291	An Automated Intervention Did Not Improve Adherence to Oral Oncolytic Agents While Managing Symptoms: Results From a Two-Arm Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 727-735.	0.6	18
292	A Roadmap to Survivorship: Optimizing Survivorship Care Plans for Adolescent and Young Adult Cancer Survivors. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 660-665.	0.7	12
293	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 24-38.	2.0	215
294	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. <i>Journal of Breast Cancer</i> , 2019, 22, 387.	0.8	3
295	Effect of a Smart Pill Bottle and Pharmacist Intervention on Medication Adherence in Patients with Multiple Myeloma New to Lenalidomide Therapy. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1244-1254.	0.5	22
296	<p>Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1745-1750.	0.8	10

#	ARTICLE	IF	CITATIONS
297	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. <i>Oral Oncology</i> , 2019, 97, 82-91.	0.8	3
298	Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence. <i>Supportive Care in Cancer</i> , 2019, 27, 3573-3581.	1.0	15
299	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<scp>DIET</scp> Study). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1076-1082.	2.3	26
300	Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. <i>Cancer</i> , 2019, 125, 3266-3274.	2.0	37
301	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1589-1599.	1.2	21
302	Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 733-740.	1.1	32
303	High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMiDs) in hematology/oncology group practices in Germany. <i>Supportive Care in Cancer</i> , 2019, 27, 4265-4271.	1.0	10
304	“It is not just any pill” Women’s experiences of endocrine therapy after breast cancer surgery. <i>European Journal of Cancer Care</i> , 2019, 28, e13009.	0.7	9
305	A Novel Approach to Better Characterize Medication Adherence in Oral Anticancer Treatments. <i>Frontiers in Pharmacology</i> , 2018, 9, 1567.	1.6	19
306	The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2019, 60, 1842-1844.	0.6	2
307	Patient-centered design in developing a mobile application for oral anticancer medications. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, S86-S95.e1.	0.7	7
308	Breast Cancer: Management and Survivorship. , 0, , .		3
309	Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM). <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-6.	1.0	4
310	Impact of mobile applications on adherence to cancer treatment: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2019, 9, e027246.	0.8	5
311	Novel Therapies in Acute Myeloid Leukemia. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150955.	0.7	9
313	THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer. <i>BMC Health Services Research</i> , 2019, 19, 977.	0.9	14
314	Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 472-487.	1.0	15
315	From telling to sharing to silence: A longitudinal ethnography of professional-patient communication about oral chemotherapy for colorectal cancer. <i>Psycho-Oncology</i> , 2019, 28, 336-342.	1.0	2

#	ARTICLE	IF	CITATIONS
316	Survivorship needs of adolescent and young adult cancer survivors: a concept mapping analysis. <i>Journal of Cancer Survivorship</i> , 2019, 13, 34-42.	1.5	52
317	Drug interactions with oral antineoplastic drugs: The role of the pharmacist. <i>European Journal of Cancer Care</i> , 2019, 28, e12944.	0.7	19
318	Adherence to oral chemotherapy: Challenges and opportunities. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1590-1598.	0.5	56
319	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 61-71.	1.0	22
320	Are illness perceptions, beliefs about medicines and Type D personality associated with medication adherence among thyroid cancer survivors? A study from the population-based PROFILES registry. <i>Psychology and Health</i> , 2020, 35, 128-143.	1.2	13
321	Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. <i>Oncologist</i> , 2020, 25, e75-e84.	1.9	14
322	Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review. <i>Journal of the National Cancer Institute</i> , 2020, 112, 443-465.	3.0	35
323	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 33-44.	1.0	25
324	Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program. <i>Supportive Care in Cancer</i> , 2020, 28, 3313-3322.	1.0	5
325	Enhancing patients' understanding of and adherence to oral anticancer medication: Results of a longitudinal pilot intervention. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1409-1421.	0.5	3
326	Real-life adherence in capecitabine therapy using two analysis methods and persistence after 6 months of treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 27, 107815522094963.	0.5	1
327	Assessment of patients' understanding of and adherence to oral anticancer medication (OAM): Results of a cross-sectional institutional pilot study. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1569-1577.	0.5	3
328	Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 517-525.	0.6	6
329	A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer. <i>Journal of International Medical Research</i> , 2020, 48, 030006052092640.	0.4	2
330	<p>Conditions for the Implementation of a Patient Education Program Dedicated to Cancer Patients Treated by Oral Anticancer Therapy</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2263-2277.	0.8	3
331	Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population. <i>Obstetrics and Gynecology</i> , 2020, 136, 1145-1153.	1.2	10
332	Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 27, 107815522094638.	0.5	0
333	Adherence to oral anticancer chemotherapies and estimation of the economic burden associated with unused medicines. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1311-1318.	1.0	3

#	ARTICLE	IF	CITATIONS
334	Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 392-398.	0.3	7
335	Experimental Evaluation of Anticancer Efficiency and Acute Toxicity of Anthrafurin for Oral Administration. <i>Pharmaceuticals</i> , 2020, 13, 81.	1.7	6
336	"Nobody Will Tell You. You've Got to Ask!" An Examination of Patient-Provider Communication Needs and Preferences among Black and White Women with Early-Stage Breast Cancer. <i>Health Communication</i> , 2021, 36, 1331-1342.	1.8	31
337	Pharmacist-Driven Oral Oncolytic Medication Education and Consent. <i>JCO Oncology Practice</i> , 2020, 16, e1209-e1215.	1.4	4
338	Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. <i>Targeted Oncology</i> , 2020, 15, 391-406.	1.7	11
339	Patient-Oncologist Communication Regarding Oral Chemotherapy During Routine Office Visits. <i>JCO Oncology Practice</i> , 2020, 16, e660-e667.	1.4	1
340	Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 189-199.	1.1	16
341	Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 186-196.	0.5	11
342	Adherence to endocrine therapy and its relation to disease-free survival among breast cancer patients visiting an outpatient clinic at Khartoum Oncology Hospital, Sudan. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 1731-1743.	0.9	8
343	Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 857-864.	0.5	12
344	Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance. <i>Breast Care</i> , 2020, 15, 236-245.	0.8	5
345	Economic burden in patients with ALK+ non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. <i>Journal of Medical Economics</i> , 2020, 23, 894-901.	1.0	8
346	The Relationship between Health Disparities, Psychosocial Functioning and Health Outcomes in Pediatric Hematology-Oncology and Stem Cell Transplant Populations: Recommendations for Clinical Care. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2218.	1.2	6
347	Influence of Traditional Chinese Medicine on Medical Adherence and Outcome in Estrogen Receptor (+) Breast Cancer Patients in Taiwan: A Real-World Population-Based Cohort Study. <i>Phytomedicine</i> , 2021, 80, 153365.	2.3	11
348	Adherence to oral chemotherapy: Evidence from a randomised clinical trial. <i>European Journal of Cancer Care</i> , 2021, 30, e13336.	0.7	3
349	Enabling sustained communication with patients for safe and effective management of oral chemotherapy: A longitudinal ethnography. <i>Journal of Advanced Nursing</i> , 2021, 77, 899-909.	1.5	4
350	Selected psychological predictors of medication adherence in the older adults with chronic diseases. <i>Nursing Open</i> , 2021, 8, 317-326.	1.1	6
352	Introduction to Pharmaceutical Care and Medication Adherence. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2021, , 1-31.	0.3	0

#	ARTICLE	IF	CITATIONS
353	Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 4969-4977.	1.0	1
354	Adherence to oral antineoplastic agents in pediatric oncology. A multicenter study. <i>Archivos Argentinos De Pediatria</i> , 2021, 119, 44-50.	0.3	1
355	Teenagers and Young Adults with Cancer: An Exploration of Factors Contributing to Treatment Adherence. <i>Journal of Pediatric Oncology Nursing</i> , 2021, 38, 190-204.	1.5	0
356	The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 13-20.	0.2	3
357	Long-Acting Formulations: A Promising Approach for the Treatment of Chronic Diseases. <i>Current Pharmaceutical Design</i> , 2021, 27, 876-889.	0.9	2
358	Patientsâ€™ Perceived Continuity of Care and Adherence to Oral Anticancer Therapy: a Prospective Cohort Mediation Study. <i>Journal of General Internal Medicine</i> , 2021, 36, 1525-1532.	1.3	2
359	Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOGâ€™ACRIN TAILORx trial. <i>Cancer</i> , 2021, 127, 2545-2552.	2.0	20
360	Treatment Adherence in Patients with Lung Cancer from Prospects of Patients and Physicians. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1891-1898.	0.5	2
361	The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study. <i>JMIR Research Protocols</i> , 2021, 10, e25271.	0.5	4
362	A mixed method study design to explore the adherence of haematological cancer patients to oral anticancer medication in a multilingual and multicultural outpatient setting: The MADESIO protocol. <i>PLoS ONE</i> , 2021, 16, e0253526.	1.1	1
363	Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2612-2624.	0.6	16
364	Use of Interventions to Overcome Medication Non-Adherence. <i>International Journal of Asian Business and Information Management</i> , 2021, 12, 289-318.	0.7	6
366	Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.1	2
367	Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review. <i>Expert Review of Hematology</i> , 2021, 14, 645-654.	1.0	1
368	Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study. <i>ESMO Open</i> , 2021, 6, 100207.	2.0	3
369	Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 165, 106-112.	2.0	0
370	Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment. <i>World Journal of Gastroenterology</i> , 2021, 27, 5424-5437.	1.4	0
371	Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2175-2184.	0.8	2

#	ARTICLE	IF	CITATIONS
372	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). <i>Leukemia and Lymphoma</i> , 2022, 63, 189-198.	0.6	3
373	Adherence to PARP inhibitor therapy among women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 262-268.	0.6	7
374	Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1543-1551.	0.5	4
375	A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e27576.	2.1	13
376	Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102264.	3.4	29
377	Fertility Communication and High-Risk Patients. , 2014, , 61-72.		2
378	Resistance to HER2-Targeted Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 35-88.	0.1	2
379	Contribution of a preliminary socio-anthropological survey to the development of a therapeutic patient education programme for patients receiving oral chemotherapy. <i>Education Therapeutique Du Patient</i> , 2010, 2, S101-S107.	0.5	7
380	Are we ready for intercultural cancer care?. <i>Current Opinion in Oncology</i> , 2018, 30, 205-211.	1.1	5
381	Ensuring optimal adherence to BCR-ABL1 tyrosine kinase inhibitor therapy for chronic myeloid leukemia. <i>Community Oncology</i> , 2013, 10, 138-146.	0.2	2
382	Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e81677.	1.1	23
383	A Nation-Wide Multicenter 10-Year (1999-2008) Retrospective Clinical Study of Endocrine Therapy for Chinese Females with Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e100159.	1.1	9
384	New Perspective in the Formulation and Characterization of Didodecyldimethylammonium Bromide (DMAB) Stabilized Poly(Lactic-co-Glycolic Acid) (PLGA) Nanoparticles. <i>PLoS ONE</i> , 2015, 10, e0127532.	1.1	42
385	Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2017, 12, e0183119.	1.1	16
386	Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARE and MEDication) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2020, 15, e0243309.	1.1	2
387	Difficult to Swallow: Issues Affecting Optimal Adherence to Oral Anticancer Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 265-270.	1.8	4
388	Literature review on Biodegradable Nanospheres for Oral and Targeted Drug Delivery. <i>Asian Journal of Biomedical and Pharmaceutical Sciences</i> , 2015, 05, 01-12.	0.1	8
389	The Persistence of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Non-Valvular Atrial Fibrillation. <i>International Journal of Arrhythmia</i> , 2016, 17, 190-199.	0.3	1

#	ARTICLE	IF	CITATIONS
390	Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. <i>Acta Clinica Belgica</i> , 2011, 66, 85-96.	0.5	73
391	Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. <i>Cancer Management and Research</i> , 2009, 1, 137.	0.9	7
392	PEGylated Nanoliposomes Potentiated Oral Combination Therapy for Effective Cancer Treatment. <i>Current Drug Delivery</i> , 2020, 17, 728-735.	0.8	10
393	Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Novel Mobile Phone-Based Intervention: Study Design of a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2014, 3, e79.	0.5	33
394	Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and Development. <i>JMIR Research Protocols</i> , 2017, 6, e62.	0.5	80
395	Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib. <i>World Journal of Gastroenterology</i> , 2018, 24, 3155-3162.	1.4	6
397	Impact of Patient Counseling on Medication Adherence, Beliefs and Satisfaction about Oral Chemotherapies in Patients with Metastatic Cancer at a Super Specialty Hospital. <i>International Journal of Cancer Research</i> , 2015, 11, 128-135.	0.2	15
398	The effect of structured education to patients receiving oral agents for cancer treatment on medication adherence and self-efficacy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2017, 4, 290-298.	0.7	30
399	Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer. <i>Indian Journal of Cancer</i> , 2017, 54, 25.	0.2	11
400	Design of Customized Mobile Application for Patient Adherence to Oral Anticancer Medications Utilizing User-Centered Design. <i>The Journal of Biocommunication</i> , 2017, 41, .	0.1	8
401	Factors Influencing Medication Adherence to Oral Anticancer Drugs. <i>Asian Oncology Nursing</i> , 2013, 13, 201.	0.2	4
402	Adherence to medication: A nation-wide study from the Children's Cancer Hospital, Egypt. <i>World Journal of Psychiatry</i> , 2013, 3, 25.	1.3	11
403	Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013, 35, 389-94.	0.7	5
404	A Tailored Nurse Coaching Intervention for Oral Chemotherapy Adherence. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, .	0.2	23
405	Adherence to Recommended Treatments for Early Invasive Breast Cancer: Decisions of Women Attending Surgeons in the Breast Cancer Audit of Australia and New Zealand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1675-1682.	0.5	7
406	Adherence to Capecitabine Treatment and Contributing Factors among Cancer Patients in Malaysia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 9225-9232.	0.5	13
407	Contribution of social and demographic parameters to the long-term survival prognosis of chronic myeloid leukemia patients. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 346-361.	0.1	1
408	Adherence to Oral Therapies for Cancer: Barriers and Models for Change. <i>Journal of the Advanced Practitioner in Oncology</i> , 2010, 1, .	0.2	2

#	ARTICLE	IF	CITATIONS
409	Verabreichung der intravenösen und oralen Tumorthherapie. , 2011, , 225-247.		0
410	Psychosociale zorg voor de kankerpatiënt. , 2011, , 605-615.		0
411	Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 174-9.	0.7	8
412	Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor. Journal of the Advanced Practitioner in Oncology, 2013, 4, .	0.2	6
413	Changes in P-glycoprotein during Treatment with Anti-cancer Drug and its Influence on Pharmacokinetics and Pharmacological Effects. Iryo Yakugaku (Japanese Journal of Pharmaceutical) Tj ETQq0 0 0 rg8.0/Overlack 10 Tf 50	0.1	0
414	Burden of Tyrosine Kinase Inhibitor Failure in Patients with Chronic Myeloid Leukemia. Journal of Leukemia (Los Angeles, Calif), 2015, 03, .	0.1	1
415	Treatment with Tyrosine Kinase Inhibitors in Chronic Myeloproliferative Neoplasms: Pros and Cons. American Journal of Internal Medicine, 2016, 4, 66.	0.1	0
416	Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	2
417	A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy. Cureus, 2016, 8, e555.	0.2	0
418	Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice. Journal of the Advanced Practitioner in Oncology, 2016, 7, 604-613.	0.2	2
419	Psychosociale zorg voor de patiënt met kanker. , 2017, , 635-646.		0
420	Home Medication Safety and Adherence. , 2017, , 239-252.		0
421	Drug Interactions in Aging and Cancer. , 2018, , 1-11.		0
422	Oral vinorelbine: a narrative review. Cancer Nursing Practice, 2018, 17, 25-33.	0.2	0
423	Feasibility of a referral pathway to community pharmacy for patients taking oral anticancer medication. Cancer Nursing Practice, 2019, 18, 22-28.	0.2	1
424	Various Challenges and Opportunities in Oral Delivery of Anticancer Drugs. Journal of Advances in Medical and Pharmaceutical Sciences, 0, , 1-18.	0.2	0
425	Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence. Journal of the Advanced Practitioner in Oncology, 2020, 11, 83-96.	0.2	2
426	Perceptions of Health-Care Workers of the Cost and Safety of Oral Oncolytic Agents for Patients: A Survey. Journal of the Advanced Practitioner in Oncology, 2020, 11, 354-365.	0.2	1

#	ARTICLE	IF	CITATIONS
427	Understanding Barriers to Oral Therapy Adherence in Adults With Acute Myeloid Leukemia. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 342-349.	0.2	1
428	SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021004.	0.5	5
430	Drug Interactions in Aging and Cancer. , 2020, , 353-363.		0
431	Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis. <i>World Journal of Meta-analysis</i> , 2020, 8, 27-40.	0.1	1
432	Connecting Patients With Specialty Products: Part 2: The future of specialty drug distribution. <i>Biotechnology Healthcare</i> , 2012, 9, 13-6.	0.2	0
433	Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models. <i>American Health and Drug Benefits</i> , 2012, 5, 242-53.	0.5	2
434	Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor. <i>Journal of the Advanced Practitioner in Oncology</i> , 2013, 4, 238-50.	0.2	6
435	A tailored nurse coaching intervention for oral chemotherapy adherence. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, 163-72.	0.2	22
437	Adherence to targeted oral anticancer medications. <i>Discovery Medicine</i> , 2013, 15, 231-41.	0.5	53
438	Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1745-1745.	0.7	2
439	Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 419-427.	0.7	0
440	Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. <i>Supportive Care in Cancer</i> , 2022, 30, 2803-2810.	1.0	3
441	Association between adherence to oral therapies in cancer patients and clinical outcome: A systematic review of the literature. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1999-2018.	1.1	6
442	Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS). <i>ESMO Open</i> , 2021, 6, 100315.	2.0	18
443	Poor Adherence to Common Recommendations and Associated Factors among Outpatients with Type 2 Diabetes Mellitus in a Police Hospital of Ethiopia. <i>Journal of Social Health and Diabetes</i> , 2021, 9, e8-e14.	0.3	0
444	Contribution of Oncology Pharmacists in Cancer Care: A Need for Quality Care. <i>Current Women's Health Reviews</i> , 2023, 19, .	0.1	0
445	Call to Action for Improving Oral Anticancer Agent Adherence. <i>Journal of Clinical Oncology</i> , 2022, 40, 1036-1040.	0.8	5
447	Pro-adherence complementary audiovisual educational intervention model for chronic myeloid leukemia patients treated with imatinib mesylate. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 521-528.	0.5	0

#	ARTICLE	IF	CITATIONS
448	Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study. <i>Breast</i> , 2022, 62, 69-74.	0.9	0
449	Living experiences of patients with advanced cancer with low socioeconomic status: protocol for a systematic review of qualitative evidence. <i>BMJ Open</i> , 2022, 12, e054606.	0.8	0
450	Adherence to Analgesics Among Outpatients Seriously Ill With Cancer. <i>Cancer Nursing</i> , 2022, Publish Ahead of Print, .	0.7	1
451	Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statementâ€”A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO. <i>Cancers</i> , 2022, 14, 1295.	1.7	4
452	Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors. <i>Annals of Behavioral Medicine</i> , 2022, 56, 856-871.	1.7	13
453	Exploring a New Theoretical Model to Explain the Behavior of Medication Adherence. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 784314.	0.6	0
454	Investigation of Intervention Solutions to Enhance Adherence to Oral Anticancer Medicines in Adults: Overview of Reviews. <i>JMIR Cancer</i> , 2022, 8, e34833.	0.9	5
456	Multicriteria decision analysis in health care decision in oncology: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 365-380.	0.7	3
457	Improving Cancer Care Through Digital Health Coaching. <i>American Journal of Medical Quality</i> , 2022, Publish Ahead of Print, .	0.2	1
458	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231.	15.2	38
459	Developing a medication adherence technologies repository: proposed structure and protocol for an online real-time Delphi study. <i>BMJ Open</i> , 2022, 12, e059674.	0.8	6
462	Adherence to hormone therapy in women with breast cancer: a quantitative study. <i>Professioni Infermieristiche</i> , 2016, 69, 113-21.	1.0	8
463	Influence of the COVID-19 Pandemic on Adherence to Orally Administered Antineoplastics. <i>Journal of Clinical Medicine</i> , 2022, 11, 2436.	1.0	1
464	Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study. <i>Cureus</i> , 2022, , .	0.2	2
465	Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 760-773.	0.2	3
467	Adherence to oral hormonal anticancer agents in breast cancer. <i>Tumori</i> , 2023, 109, 262-268.	0.6	1
468	Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy. <i>Cancer Causes and Control</i> , 2022, 33, 1145-1153.	0.8	2
469	A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1806-1815.	0.5	2

#	ARTICLE	IF	CITATIONS
470	Feasibility and Quality Validation of a Mobile Application for Enhancing Adherence to Opioids in Sickle Cell Disease. <i>Healthcare (Switzerland)</i> , 2022, 10, 1506.	1.0	1
471	A mixed-methods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 393-399.	1.1	2
472	Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA). <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022, 7, 100163.	0.6	0
473	Home is best. Self-administration of subcutaneous Bortezomib at home in patients with multiple myeloma - A mixed method study. <i>European Journal of Oncology Nursing</i> , 2022, 60, 102199.	0.9	2
475	Follow-up and Cancer Survivorship. <i>Surgical Clinics of North America</i> , 2023, 103, 169-185.	0.5	3
476	Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine. <i>Leukemia and Lymphoma</i> , 2023, 64, 525-539.	0.6	0
477	Initiatives to Improve Safety of Oral Anticancer Agents Delivered by Community Pharmacists. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 60-68.	3.0	0
478	Facing point of views: Representations on adjuvant endocrine therapy of premenopausal patients after breast cancer and their healthcare providers in France. The FOR-AD study. <i>European Journal of Oncology Nursing</i> , 2022, , 102259.	0.9	0
479	Does age play a role in fever and neutropenia events and complications: A comparison of adolescents versus younger children with cancer at a tertiary care pediatric hospital, a pilot project. <i>Cancer Reports</i> , 0, , .	0.6	1
480	Adherence to Oral Chemotherapy in Acute Lymphoblastic Leukemia during Maintenance Therapy in Children, Adolescents, and Young Adults: A Systematic Review. <i>Current Oncology</i> , 2023, 30, 720-748.	0.9	5
481	Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?. <i>Current Oncology</i> , 2023, 30, 392-400.	0.9	6
482	Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer. <i>Clinical Drug Investigation</i> , 2023, 43, 167-176.	1.1	0
483	Patient Safety Management Practiced by Pharmacy Pharmacists Using Their Training at Oncology Hospital. <i>Yakugaku Zasshi</i> , 2023, 143, 223-228.	0.0	0
484	[Translated article] Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs. <i>Farmacia Hospitalaria</i> , 2023, 47, T69-T74.	0.6	0